Abstract
The article presents the results of milk thistle schroth administration to reduce viral load in patients with chronic viral hepatitis С. These patients did not respond to combined antiviral therapy with peginterferon and ribavirin. Milk thistle schroth contains silymarin (a mixture of 7 compounds called flavolignans) and administrated at a dosage of 1 g/kg body weight in 39 patient, which is much higher than the dosages used in previous studies. 50 days after the administration of schroth in 28 patients (72% of all patients) there were a significant reduction of viral load and ALT activity to 5,1 times and 1,7 times, respectively. In
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
